Arrowhead’s small interfering RNA therapy reduced triglycerides and lowered pancreatitis risk in the phase 3 PALISADE trial, providing a quarterly self-administered option for patients with familial chylomicronemia syndrome.
Regular pharmaceutical opioid use was found to be associated with an elevated risk for cancers previously associated with opium consumption, but not for other cancers, according to findings from a lar...
The FDA’s authorization of the Q-Collar is under scrutiny after researchers identified duplicated data, altered study endpoints, and unsubstantiated “brain protection” claims.
Proposed cuts to the Hospital Preparedness Program may limit hospitals’ capacity to manage pandemics, natural disasters, and mass-casualty events affecting U.S. health systems.